P-200 MAP4K2 inhibition reinforces sensitivity to iberdomide in RAS-mutated MM through a CRBN-independent mechanism

Li, S., Fu, J., Liu, G., Ma, H., Mapara, M., Marcireau, C., & Lentzsch, S. (2023). P-200 MAP4K2 inhibition reinforces sensitivity to iberdomide in RAS-mutated MM through a CRBN-independent mechanism. Clinical Lymphoma Myeloma and Leukemia, 23, S145–S146. https://doi.org/10.1016/s2152-2650(23)01818-9

Authors:

Shirong Li

Jing Fu

Guifen Liu

Huihui Ma

Markus Y. Mapara

Christophe Marcireau

Suzanne Lentzsch

Affiliated Authors:

Shirong Li

Jing Fu

Guifen Liu